Medication company Viatris (NASDAQ: VTRS) missed Wall Street’s revenue expectations in Q3 2026, with revenue flat year on year at $3.75 billion. On the other hand, the company’s outlook for the full year was close to analysts’ consensus estimates, with revenue guided to $14.8 billion at the midpoint. Its non-GAAP profit of $0.71 per share was 11.3% above analysts’ consensus estimates.

For more on Viatris, read our free full research report.

Revenue growth

Examining a company’s long-term performance can provide clues about its quality. Any business can experience short-term success, but top-performing ones sustain growth for years. Over the last five years, Viatris’s demand was weak and its revenue declined by 3% per year. This was below our standards and suggests it’s a low-quality business.

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Viatris’s annualized revenue declines of 1.1% over the last two years suggest its demand continued shrinking.

This quarter, Viatris’s $3.75 billion of revenue was flat year on year, falling short of Wall Street’s consensus estimates.

Looking ahead, sell-side analysts expect revenue to grow 2.8% over the next 12 months, according to S&P. While this projection implies its newer products and services will spur better top-line performance, it is still below average for the sector.

Adjusted operating margin

Viatris has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, with an average adjusted operating margin of 28.6%.

Looking at the trend in its profitability, Viatris’s adjusted operating margin decreased by 11.5 percentage points over the last five years. The company’s two-year trajectory also shows it failed to return profitability to its peak as its margin fell by 6.7 percentage points. This performance was poor, showing that its expenses were rising and it couldn’t pass those costs on to its customers.

This quarter, Viatris generated an adjusted operating margin of 8%, down 19.8 percentage points year on year. This contraction shows it was less efficient because its expenses increased relative to its revenue.

Earnings per share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth. For example, a company could inflate its revenue through excessive spending on advertising and promotions.

Viatris’s EPS declined by 6.1% annually over the last five years, more than its revenue. This indicates the company struggled because its fixed cost base made it difficult to adjust to shrinking demand.

A closer look at Viatris’s earnings helps explain its performance. As noted earlier, Viatris’s adjusted operating margin declined by 11.5 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q3, Viatris reported adjusted EPS of $0.71, up from $0.67 in the same quarter last year. The result was well above analysts’ consensus estimates, a positive for shareholders. Over the next 12 months, Wall Street expects Viatris’s full-year EPS to grow 3% from $2.56 to $2.64, according to S&P.

Key takeaways from Viatris’s Q3 results

Viatris’s full-year EPS guidance topped analysts’ consensus estimates, and quarterly EPS also beat Wall Street’s consensus. Revenue came in slightly below expectations, but the quarter still had some key positives. Shares remained flat at $19.39 immediately after the report.

When deciding whether to invest in this stock, the latest quarter matters, but not as much as longer-term business quality and valuation. For more on Viatris, read the full research report here (it’s free).